Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 4/20 | 0.46 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.43 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6448853 | 0.82 | GUSB (0.43) | CYP19A1KMT2AMEN1KDM4EMAPT | |
| SCHEMBL6448858 | 0.81 | SYK (0.55) | GRIN1GRIN2BSYKSLC16A3SLC16A1 | |
| SCHEMBL6450170 | 0.77 | MAPT (0.48) | SLC16A3CYP19A1HSP90AA1L3MBTL1KMT2A | |
| SCHEMBL6448346 | 0.76 | CYP19A1 (0.46) | GRIN1GRIN2BSYKPLA2G2ACYP19A1 | |
| SCHEMBL29167678 | 0.72 | SYK (0.48) | SYKCYP19A1L3MBTL1KMT2AMEN1 | |
| SCHEMBL8625863 | 0.71 | PLA2G2A (0.53) | GRIN1GRIN2BSYKSLC16A3SLC16A1 | |
| SCHEMBL28683062 | 0.68 | KDM4E (0.48) | SYKL3MBTL1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL6454291 | 0.67 | HTT (0.42) | SYKMAPTSMN1; SMN2 | |
| SCHEMBL5326831 | 0.67 | IDH1 (0.58) | SYKCYP19A1HSP90AA1L3MBTL1KMT2A | |
| SCHEMBL31130264 | 0.67 | SLC16A3 (0.69) | GRIN1GRIN2BSYKSLC16A3SLC16A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | GRIN1 4772/4885GRIN2B 4832/4885SYK 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.